To investigate the effect of SH2 domain-containing protein-tyrosine phosphatase-2 (SHP-2) activation mutation on apoptosis and proliferation of human glioma cells, and to find a new target for inhibiting malignant transformation.

The design of pcDNA3.1 loaded SHP-2D61Gmutant activating mutation plasmid was transfected into U521 glioma cells, and the cells stably expressing SHP-2 were used as a mutation group. The cells transfected with empty plasmid without activating mutation gene were regarded as an empty group, and non-transfected cells served as a normal control group. Three groups of cells were cultured under the same condition. And the cell proliferation, invasion and cell apoptosis was measured to evaluate the apoptosis and proliferation of glioma cells. The t test and c² test were used as statistical analysis, and multiple comparisons between groups were performed by SNK-q test.

Compared with the normal control group and empty vector group, the proliferation rate and activity of the transfected cells were significantly increased after 24 h (t = 13.236,16.782, P < 0.01) ; the invasion ability of the mutant cells was significantly increased [ (431.25±4.98) vs (66.05?±5.13) , (t = 22.343, P < 0.01) ; (431.25±4.98) vs (67.11±5.25) , (t = 26.112, P < 0.01) ], and the apoptosis rate was significantly reduced (8.23﹪ vs 33.76﹪, 8.23﹪ vs 26.77﹪, t = 32.267, 22.982, P < 0.01) .

SHP-2 activating mutation could improve the proliferation rate, invasion ability and cell viability of glioma cells, and change the malignant biological behavior. The result suggested that this protein may be a new target for malignant transformation.